"For the twelve months ending September 2011, Dilaudid(R) 8 mg tablets and its generic equivalents had total U.S. sales of approximately $30 million according to IMS Health Data. and there are currently four other approved generic manufacturers plus the innovator.
So with Elite there are six companies to split up the $30,000,000 market. Elite's partner, TAGI, would do well to see $2,000,000 in SALES, NOT PROFIT. Plus Elite only gets a piece of the sales in the form of a license fee + the milestone payments.
This won't boost the PPS much. We need several more announcements and a good 10Q to get going.
hey turdboy, where did you get your DD from. exactly the CC's prs and 10qs on top you and your side kick just reword and type or paste and send. boy thats real hard to do you DA. but what sad is all the pumping and the PPS is sliding again.